Population Burden of STI and Implication for Intervention in Hong Kong

March 14, 2025 updated by: Ngai Sze WONG, Chinese University of Hong Kong

Population Burden of Sexually Transmitted Infections and Implication for Intervention in Hong Kong

This is a 5-year cross-disciplinary sexually transmitted infection (STI) project involving a) territory-wide and community-based studies (survey and specimen collection); b) simulation of STI transmission dynamics and comparison of STI intervention strategies through mathematical modelling and cost-effectiveness analysis. The aim of this project is to assess the burden and the transmission dynamics of STIs in the general population and men who have sex with men (MSM) in Hong Kong. Around 1300 sexually experienced adults and 900 MSM would be recruited, 100 participants would be invited for individual in-depth interviews. Main outcome measures include STI history and service preference, effectiveness as measured by the proportion of new STI infections (chlamydia, gonorrhoea and human papillomavirus infections) averted above base-case scenario, and incremental cost-effectiveness ratio.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

After completion of baseline questionnaire, the participants are invitied for STI self-sampling. If agree, a package of self-sampling kits, instructions, and packaging materials for return post would be delivered to their selected collection points. The second round of self-sampling would be offered at least one year from the first round of self-sampled specimens collected.

Study Type

Observational

Enrollment (Actual)

1977

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
    • Hong Kong, China
      • Hong Kong, Hong Kong, China, Hong Kong, 0000
        • The Chinese University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

sexually experienced adults

Description

Inclusion Criteria:

  • aged 18 or above
  • ever having sex
  • normally living in Hong Kong
  • can communicate in English or Chinese

Exclusion Criteria:

  • failed to provide consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
General population
sexually experienced adults (aged 18 or above) of the randomly selected household
Other: self-sampling kits for STI testing in laboratory
participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
men who have sex with men
men who have sex with men aged 18 or above and normally living in Hong Kong
Other: self-sampling kits for STI testing in laboratory
participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
self-reported STI diagnosis in questionnaire
Time Frame: up to 2 years
number of STI diagnosis
up to 2 years
effectiveness of STI intervention strategies
Time Frame: 10 years
incremental cost-effectiveness ratio
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
STI symptom reported in questionnaire
Time Frame: 12 months
types of symptom presentations
12 months
willingness to pay for STI testing reported in questionnaire
Time Frame: 12 months
willingness to pay (HKD)
12 months
prevalence of STI estimated through laboratory testing
Time Frame: 12 months
prevalence of chlamydia trachomatis, Neisseria gonorrhoeae and human papillomavirus infections from self-collected samples
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Investigators

  • Principal Investigator: Ngai Sze Wong, PhD, Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 13, 2021

Primary Completion (Actual)

December 31, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

February 1, 2021

First Submitted That Met QC Criteria

March 9, 2021

First Posted (Actual)

March 11, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 14, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CID-CUHK-E

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on STI

Clinical Trials on self-sampling kits for STI testing in laboratory

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe